Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1852 - Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)

Date

10 Sep 2017

Session

Poster display session

Presenters

Johann de Bono

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

J. de Bono1, S. Bracarda2, K. Chi3, C. Massard4, D. Olmos Hidalgo5, S. Sandhu6, C.N. Sternberg7, S. Gendreau8, N. Xu9, T. Baney10, D. Maslyar11, C.J. Sweeney12

Author affiliations

  • 1 Division Of Clinical Studies And Experimental Medicine, Institute of Cancer Research and The Royal Marsden Hospital, SM2 5PT - London/GB
  • 2 Medical Oncology, Department Of Oncology, Azienda USL Toscana Sud-Est, Istituto Toscano Tumori (ITT) and Ospedale San Donato, Arezzo/IT
  • 3 Clinical Trials Unit, BC Cancer Agency, Vancouver, British Columbia/CA
  • 4 Early Drug Development Department, Institut de Gustave Roussy, Villejuif/FR
  • 5 Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, 028029 - Madrid/ES
  • 6 Department Of Oncology, Peter MacCallum Cancer Center, 3002 - Melbourne/AU
  • 7 Department Of Oncology, San Camillo and Forlanini Hospitals, 156 - Roma/IT
  • 8 Late Stage Biomarker Development, Genentech Inc., 94080 - South San Francisco/US
  • 9 Biostatistics - Oncology Solid Tumor, Genentech Inc., 94080 - South San Francisco/US
  • 10 Product Development Oncology, Genentech Inc., 94080 - South San Francisco/US
  • 11 Product Development Clinical Oncology, Genentech Inc., 94080 - South San Francisco/US
  • 12 Medical Oncology Department, Dana-Farber Cancer Institute, Boston/US
More

Resources

Abstract 1852

Background

In a Phase Ib/II study, the small-molecule AKT inhibitor ipatasertib in combination with abiraterone and prednisone/prednisolone demonstrated an improved radiographic progression-free survival (rPFS) vs abiraterone and prednisone/prednisolone alone, with greater benefit in patients with phosphatase and tensin homolog (PTEN)–loss tumors. This randomized Phase III trial will evaluate the efficacy, safety and pharmacokinetics (PK) of ipatasertib vs placebo (both combined with abiraterone and prednisone/prednisolone) in patients with previously untreated mCRPC.

Trial design

Eligible patients must have untreated asymptomatic or mildly symptomatic mCRPC with progressive disease by Prostate Cancer Clinical Trials Working Group 3 criteria, ongoing androgen deprivation therapy or castrated state and ECOG PS 0 or 1. Treatments with second-generation CYP450 inhibitors or androgen-receptor blockers and untreated or active central nervous system metastases are not allowed; however, prior chemotherapy for hormone-sensitive disease is permitted. Eligible cases will be randomized 1:1 to abiraterone 1000 mg QD + prednisone/prednisolone 5 mg BID plus ipatasertib 400 mg QD or placebo. Crossover between treatment arms is not allowed. Stratification factors are prior taxane-based therapy in the hormone-sensitive setting, progression factor (prostate-specific antigen [PSA] only vs other), presence of liver or lung metastasis, tumor PTEN status by immunohistochemistry (loss vs non-loss) and geographic region. The primary efficacy endpoint is investigator-assessed rPFS (intent-to-treat population and patients with PTEN-loss tumors). Additional endpoints include time to pain progression, time to next cytotoxic chemotherapy, overall survival, additional patient-reported outcomes, time to first opioid use, time to PSA progression, safety and PK. Approximately 850 patients will be enrolled at ∼200 centers worldwide.

Clinical trial identification

NCT03072238.

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd

Funding

F. Hoffmann-La Roche Ltd

Disclosure

J. de Bono: Scientific advisor: Genentech/Roche Advisory boards: AstraZeneca/MedImmune, Boehringer Ingelheim, GenMab, Glaxo-Smith Kline, Medivation, Merck, Novartis, Pfizer, Sanofi, Vertex, Taiho and Daiichi. S. Bracarda: Advisory Board Member for: Pfizer, Novartis, BMS, Roche, Genentech, MSD, IPSEN, Eusa Pharma, Astellas; Honoraria from: Pfizer, Astellas, Jannsen, Novartis, BMS Travel Reimbursement: Bayer, BMS, Astellas, Jannsen, Ipsen. K. Chi: Adviser and honoraria from Roche/Genetech. C. Massard: Advisory boards, speaker or investigator for: Amgen, Astellas, AstraZeneca, Bayer, Celgene, Genentech, Ipsen, Jansen, Lilly, Novartis, Pfizer, Roche, Sanofi Orion. D. Olmos Hidalgo: Advisory boards for Gentech/Roche (Ipasertib - international - and in local advisory boards of atezolizumab), advisory boards of Janssen, research funding from Janssen. C.N. Sternberg: Research funding to department or consulted: Astellas, Bayer, Janssen, Roche/Genentech, Sanofi, Novartis. S. Gendreau: Employee of Genentech. N. Xu: Employee of Roche and own Roche stocks. T. Baney, D. Maslyar: Employee at Genentech and own stock. C.J. Sweeney: Consultant with compensation: Astellas, Bayer, Genentech, Janssen, Pfizer, Sanofi Research Funding: Astellas, Janssen, Sotio, Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.